FDA approves RASONQUE after 500-patient trial nearly doubles pancreatic cancer survival
Revolution Medicines’ once-daily daraxonrasib improved median overall survival to 13.2 months from 6.7 months with chemotherapy in RASolute 302, giving metastatic pancreatic adenocarcinoma its first FDA-approved broad RAS-targeted therapy.